Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

JAMA Network

Phase II single arm data of frontline Ibrutinib and venetoclax in older or high risk patients with CLL. Patients had either del(17p), TP53-mutated, del(11q),

  • Phase II single arm data of frontline Ibrutinib and venetoclax in older or high risk patients with CLL. Patients had either del(17p), TP53-mutated, del(11q), unmutated IgVH, or age 65 years or older. 75% of patients achieved marrow uMRD as best response. Estimated 3 year PFS was 93%.